Quick Takeaways
- IMNM - Immunome Inc. has 26 insiders with reported activity on this page.
- Net insider value flow over the last year: -$9,249,730.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 26 Insiders of Immunome Inc.
- Symbol
- IMNM on Nasdaq
- Location
- Bothell, WA
What Changed
- Buy value: $2,045,130; sell value: $11,294,860.
- Net share flow: -421,670.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$9,249,730.
Buys
$2,045,130
Shares: 100,968
Insiders: 3
Sells
$11,294,860
Shares: 522,638
Insiders: 4
Net
-$9,249,730
Shares: -421,670
Insiders: -1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 27,450 | 139,438 | $544,272 | $2,964,780 | -$2,420,509 |
| 3-6 | 68,518 | 383,200 | $1,453,958 | $8,330,080 | -$6,876,121 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 5,000 | 0 | $46,900 | $0 | +$46,900 |
Immunome Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Isaac Barchas | Director | $46,797,554 | -$8,330,080 | -15% | Mixed | 22 Dec 2025 |
| Clay B. Siegall | President and CEO, Director | $13,586,147 | +$1,749,660 | +15% | Filing P/S | 27 Mar 2026 |
| Michael Rapp | Director | $7,564,292 | Mixed | 02 Oct 2023 | ||
| Philip Wagenheim | Director | $7,044,685 | -$1,335,626 | -16% | Filing P/S | 20 Mar 2026 |
| Max Rosett | Chief Financial Officer | $1,214,751 | -$1,424,916 | -54% | Filing P/S | 02 Apr 2026 |
| Philip Tsai | Chief Technical Officer | $887,216 | +$204,900 | +30% | Filing P/S | 19 Dec 2025 |
| Jean J. Bienaime | Director | $827,843 | +$90,570 | +12% | Filing P/S | 10 Mar 2026 |
| Jack Higgins | Chief Scientific Officer | $540,520 | -$204,238 | -27% | Mixed | 02 Apr 2026 |
| Franklyn G. Prendergast | Director | $359,564 | Mixed | 02 Oct 2023 | ||
| Bruce Turner | Chief Strategy Officer | $249,993 | Filing P/S | 09 Aug 2024 | ||
| Robert Lechleider | Chief Medical Officer | $149,800 | Filing P/S | 29 Jul 2025 | ||
| Bob Lapetina | PAO and VP Finance & Corporate | $71,198 | Mixed | 02 Jan 2024 | ||
| John L. Lamattina | Director | Mixed | 08 Jun 2023 | |||
| Purnanand D. Sarma | President and CEO, Director | Mixed | 08 Jun 2023 | |||
| Richard A. Baron | Director | Mixed | 08 Jun 2023 | |||
| Carol Schafer | Director | Mixed | 10 Jun 2025 | |||
| Phil Noland Roberts | Chief Technology Officer | Mixed | 13 Dec 2023 | |||
| Michael Widlitz | Director | Mixed | 28 May 2021 | |||
| Michael Lefenfeld | Director | Mixed | 08 Jun 2023 | |||
| Dennis H. Giesing | Chief Development Officer | Mixed | 08 Jun 2023 | |||
| Sandra M. Swain | Director | Mixed | 10 Jun 2025 | |||
| Corleen M. Roche | Chief Financial Officer | Mixed | 08 Jun 2023 | |||
| Kinney Horn | Chief Business Officer | Mixed | 29 Jul 2025 | |||
| Sandra G. Stoneman | Chief Legal Officer & Gc | Mixed | 29 Jul 2025 | |||
| Matthew K. Robinson | Chief Technology Officer | Mixed | 08 Jun 2023 | |||
| James P. Boylan | Director | Mixed | 10 Jun 2025 |
Top shareholders of Immunome Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
15%
from 13D/G
|
16,549,716
|
$355,487,900 | — | 31 Dec 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
|
Company |
12%
from 13D/G
|
13,421,987
|
$288,305,000 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.9%
|
7,594,996
|
$163,140,515 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
5.9%
from 13D/G
|
7,034,952
|
$151,110,769 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.5%
|
6,038,414
|
$129,705,133 | — | 31 Dec 2025 | |
| Redmile Group, LLC |
13F
13D/G
|
Company |
5.2%
from 13D/G
|
5,718,385
|
$122,830,910 | — | 31 Dec 2025 | |
| Enavate Sciences GP, LLC |
13F
13D/G
|
Company |
4.3%
from 13D/G
|
4,768,583
|
$102,429,163 | — | 31 Dec 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
4.3%
|
4,685,441
|
$100,643,273 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.5%
|
3,868,000
|
$83,084,640 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.4%
|
3,705,974
|
$79,604,322 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3.1%
|
3,380,240
|
$72,608,000 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.6%
|
2,855,747
|
$61,341,446 | — | 31 Dec 2025 | |
| EcoR1 Capital, LLC |
13F
13D/G
|
Company |
4.7%
from 13D/G
|
2,855,590
|
$61,338,073 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,361,381
|
$50,731,482 | — | 31 Dec 2025 | |
| Isaac Barchas |
3/4/5
|
Director |
—
mixed-class rows
|
2,142,256
mixed-class rows
|
$46,797,554 | -$8,330,080 | 22 Dec 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
1.8%
|
2,000,000
|
$42,960,000 | — | 31 Dec 2025 | |
| Immunome Aggregator, LP |
13D/G
|
— |
6%
|
4,768,583
|
$40,628,327 | $0 | 31 Jan 2025 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
1.7%
|
1,843,210
|
$39,592,151 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.6%
|
1,740,705
|
$37,390,343 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.6%
|
1,709,089
|
$36,711,252 | — | 31 Dec 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
1.5%
|
1,618,477
|
$34,764,886 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
1,575,398
|
$33,839,549 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.3%
|
1,429,680
|
$30,709,526 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
1.3%
|
1,404,450
|
$30,167,586 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1%
|
1,126,210
|
$24,190,991 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.85%
|
934,463
|
$20,072,265 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.76%
|
840,689
|
$18,058,000 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
|
Company |
2.2%
from 13D/G
|
832,078
|
$17,873,800 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.75%
|
828,701
|
$17,800,497 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.72%
|
793,364
|
$17,041,459 | — | 31 Dec 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.71%
|
779,578
|
$16,745,335 | — | 31 Dec 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.69%
|
759,192
|
$16,307,444 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.68%
|
752,725
|
$16,168,533 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.67%
|
737,116
|
$15,833,252 | — | 31 Dec 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.67%
|
732,512
|
$15,734,358 | — | 31 Dec 2025 | |
| NAN FUNG TRINITY (HK) Ltd |
13F
|
Company |
0.65%
|
714,553
|
$15,348,598 | — | 31 Dec 2025 | |
| Clay B. Siegall |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
1,490,704
mixed-class rows
|
$13,586,147 | +$1,749,660 | 27 Mar 2026 | |
| S.c.a. Candriam |
13F
|
Individual |
0.49%
|
539,882
|
$11,597,159 | — | 31 Dec 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.4%
|
435,123
|
$9,346,442 | — | 31 Dec 2025 | |
| Michael Rapp |
3/4/5
|
Director |
—
class O/S missing
|
1,279,914
|
$7,564,292 | — | 02 Oct 2023 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.32%
|
347,666
|
$7,467,866 | — | 31 Dec 2025 | |
| Atika Capital Management LLC |
13F
|
Company |
0.3%
|
334,341
|
$7,181,644 | — | 31 Dec 2025 | |
| Philip Wagenheim |
3/4/5
|
Director |
—
mixed-class rows
|
360,011
mixed-class rows
|
$7,044,685 | -$1,335,626 | 20 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.29%
|
316,383
|
$6,795,541 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.28%
|
307,194
|
$6,598,528 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.27%
|
293,750
|
$6,309,750 | — | 31 Dec 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.26%
|
286,355
|
$6,150,905 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.25%
|
277,812
|
$5,967,402 | — | 31 Dec 2025 | |
| Monashee Investment Management LLC |
13F
|
Company |
0.25%
|
274,861
|
$5,904,014 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.25%
|
270,065
|
$5,800,995 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Immunome Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jack Higgins | IMNM | Common Stock | Sale | -30% | $204,238 | $21.64 | -9,438 | 22,000 | 02 Apr 2026 | Direct |
| Max Rosett | IMNM | Common Stock | Sale | -54.6% | $1,424,916 | $21.92 | -65,000 | 54,037 | 02 Apr 2026 | Direct |
| Max Rosett | IMNM | Common Stock | Options Exercise | 150.7% | 71,561 | 119,037 | 02 Apr 2026 | Direct | ||
| Max Rosett | IMNM | Stock option (right to buy) | Options Exercise | -100% | -71,561 | 0 | 02 Apr 2026 | Direct | ||
| Jack Higgins | IMNM | Common Stock | Gift | -16.7% | -6,291 | 31,438 | 30 Mar 2026 | Direct | ||
| Clay B. Siegall | IMNM | Common Stock | Purchase | 3.83% | $500,602 | $19.67 | 25,450 | 690,704 | 27 Mar 2026 | Direct |
| Philip Wagenheim | IMNM | Common Stock | Sale | -7.64% | $582,330 | $20.65 | -28,200 | 341,147 | 23 Mar 2026 | Direct |
| Philip Wagenheim | IMNM | Common Stock | Sale | -9.06% | $753,296 | $20.47 | -36,800 | 369,347 | 20 Mar 2026 | Direct |
| Jean Jacques Bienaime | IMNM | Common Stock | Purchase | 2.67% | $21,550 | $21.55 | 1,000 | 38,415 | 11 Mar 2026 | Direct |
| Jean Jacques Bienaime | IMNM | Common Stock | Purchase | 2.75% | $22,120 | $22.12 | 1,000 | 37,415 | 10 Mar 2026 | Direct |
| Clay B. Siegall | IMNM | Common Stock | Purchase | 0.72% | $100,018 | $21.15 | 4,729 | 665,254 | 30 Dec 2025 | Direct |
| Isaac Barchas | IMNM | Common Stock | Sale | -0.55% | $251,347 | $22.34 | -11,251 | 2,031,181 | 22 Dec 2025 | See footnote |
| Isaac Barchas | IMNM | Common Stock | Sale | -15.4% | $8,078,732 | $21.72 | -371,949 | 2,042,432 | 22 Dec 2025 | See footnotes |
| Jack Higgins | IMNM | Common Stock | Gift | 1,000 | 1,000 | 19 Dec 2025 | As Custodian for Child 3 | |||
| Jack Higgins | IMNM | Common Stock | Gift | 1,000 | 1,000 | 19 Dec 2025 | As Custodian for Child 2 | |||
| Jack Higgins | IMNM | Common Stock | Gift | 1,000 | 1,000 | 19 Dec 2025 | As Custodian for Child 1 | |||
| Jack Higgins | IMNM | Common Stock | Gift | -7.37% | -3,000 | 37,729 | 19 Dec 2025 | Direct | ||
| Clay B. Siegall | IMNM | Common Stock | Gift | -23.2% | -200,000 | 660,525 | 19 Dec 2025 | Direct | ||
| Clay B. Siegall | IMNM | Common Stock | Purchase | 0.85% | $149,053 | $20.48 | 7,278 | 860,525 | 19 Dec 2025 | Direct |
| Philip Tsai | IMNM | Common Stock | Purchase | 30% | $204,900 | $20.49 | 10,000 | 43,300 | 19 Dec 2025 | Direct |
| Clay B. Siegall | IMNM | Common Stock | Purchase | 5.77% | $999,986 | $21.50 | 46,511 | 853,247 | 18 Dec 2025 | Direct |
| Jack Higgins | IMNM | Common Stock | Options Exercise | 117.5% | 22,000 | 40,729 | 10 Sep 2025 | Direct | ||
| Jack Higgins | IMNM | Employee Stock option (right to buy) | Options Exercise | -12.7% | -22,000 | 151,840 | 10 Sep 2025 | Direct | ||
| Philip Tsai | IMNM | Employee Stock Option (right to buy) | Award | 190,000 | 190,000 | 29 Jul 2025 | Direct | |||
| Max Rosett | IMNM | Employee Stock Option (right to buy) | Award | 207,000 | 207,000 | 29 Jul 2025 | Direct | |||
| Robert Lechleider | IMNM | Employee Stock Option (right to buy) | Award | 242,000 | 242,000 | 29 Jul 2025 | Direct | |||
| Kinney Horn | IMNM | Employee Stock Option (right to buy) | Award | 161,000 | 161,000 | 29 Jul 2025 | Direct | |||
| Jack Higgins | IMNM | Employee Stock Option (right to buy) | Award | 196,000 | 196,000 | 29 Jul 2025 | Direct | |||
| Clay B. Siegall | IMNM | Employee Stock Option (right to buy) | Award | 800,000 | 800,000 | 29 Jul 2025 | Direct | |||
| Sandra G. Stoneman | IMNM | Employee Stock Option (right to buy) | Award | 190,000 | 190,000 | 29 Jul 2025 | Direct | |||
| James P. Boylan | IMNM | Director Stock Option (right to buy) | Award | 18,864 | 18,864 | 10 Jun 2025 | Direct | |||
| Carol Schafer | IMNM | Director Stock Option (right to buy) | Award | 18,864 | 18,864 | 10 Jun 2025 | Direct | |||
| Philip Wagenheim | IMNM | Director Stock Option (right to buy) | Award | 18,864 | 18,864 | 10 Jun 2025 | Direct | |||
| Isaac Barchas | IMNM | Director Stock Option (right to buy) | Award | 18,864 | 18,864 | 10 Jun 2025 | Direct | |||
| Jean Jacques Bienaime | IMNM | Director Stock Option (right to buy) | Award | 18,864 | 18,864 | 10 Jun 2025 | Direct | |||
| Sandra M. Swain | IMNM | Director Stock Option (right to buy) | Award | 18,864 | 18,864 | 10 Jun 2025 | Direct | |||
| Jean Jacques Bienaime | IMNM | Common Stock | Purchase | 15.9% | $46,900 | $9.38 | 5,000 | 36,415 | 03 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.